Resultados de la búsqueda 191-200 of 8435 for vaccinations

  1. Poliomielitis - Síntomas y causas - Mayo Clinic

    Polio vaccination recommendations for specific groups. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/vaccines/vpd/polio/hcp ...

  2. Ensayos clínicos - Centro Pediátrico de Mayo Clinic

    This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has come ...

  3. Transplant Center de Mayo Clinic - Ensayos clínicos

    African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test ...

  4. Mayo Clinic Medical Professional Preferences

    Cancer. Quarterly eNewsletter that focuses on trends and advances in hematology and oncology at Mayo Clinic · Cardiovascular · Clinical Updates · Digestive ...

  5. Hematología - Ensayos clínicos - Mayo Clinic

    REVOLUTION will be a multicenter registry enrolling approximately 2,500 patients. Additional patients limited to those with EGFR mutations may be enrolled ...

  6. Nutrición y comida saludable Noticias de la Mayo Clinic

    Puedes hacerte experto en comida saludable aprendiendo cómo planear comidas y hacer compras de manera inteligente, y practicando técnicas para preparar ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Durvalumab is FDA approved for treatment in lung ...

  8. Mayo Clinic Digestive Diseases Physician Update - September 2023

    Page 1.

  9. Obstetricia y Ginecología - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to evaluate olaparib and temozolomide in treating patients with uterine leiomyosarcoma (LMS) that has spread to other places of ...

  10. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    placebo in combination with ado-trastuzumab emtansine (TTT-DM1) in patients with stage II-III HER2+ breast cancer with residual disease post-neoadjuvant ...